Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Similars in SciELO
Share
Gaceta médica de México
On-line version ISSN 2696-1288Print version ISSN 0016-3813
Abstract
VALLE-SOLIS, Aura Erazo et al. Supervivencia en cáncer de mama por subtipo mediante inmunohistoquímica: Un estudio retrospectivo. Gac. Méd. Méx [online]. 2019, vol.155, suppl.1, pp.50-55. Epub July 01, 2021. ISSN 2696-1288. https://doi.org/10.24875/gmm.19005133.
Background:
Breast cancer subtype classification according to hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) using immunohistochemistry is the standard practice for therapeutic decision making.
Objective:
To design future studies information on characteristics and survival of each subtype is essential.
Method:
We conducted a retrospective study to analyze clinical and pathologic features as well as survival data according to breast cancer immunohistochemistry subtype.
Results:
There were 211 women with a RH(+)/HER2(–) breast cancer subtype, 53 HR(+)/HER2(+), 16 HER2(+) and 23 HR(–)/HER2(–), with a median overall survival in months of 39 (20.5-62.7), 42 (25.5-65), 42 (13.7-67.7) and 26 (11-78), respectively, for a 3.7 hazard ratio of death (95% Confidence Interval [CI]: 1.3-10.3) for the triple negative group as compared to the HR(+)/HER2(–) group (p = 0.01).
Conclusions:
HR positive subtypes by immunohistochemistry where most frequent and showed a greater overall survival compared to the triple negative subtype.
Keywords : Breast cancer; Immunohistochemistry; Molecular subtype; Survival.